Hologic ThinPrep 20 years - CAP-ACPcap-acp.com/2016/images/Hologic_ThinPrep_20_years... · Regional...
1
Visit ThinPrep.com to learn more. References: 1. National Cancer Institute. SEER Stat Fact Sheets: Cervix Uteri Cancer. http://seer.cancer.gov/statfacts/html/cervix.html. Accessed April 28, 2016. 2. Hologic, Inc. Data on File. 3. ThinPrep 2000 System [package insert]. MAN-02060-002 Rev. 001. Marlborough, MA: Hologic, Inc.; 2011. 4. U.S. News & World Report. Best Hospitals for Adult Gynecology. http://health.usnews.com/best-hospitals/rankings/ gynecology. Published 2016. Accessed April 28, 2016. 5. Blatt, et al. Comparison of Cervical Cancer Screening Results Among 256,648 Women in Multiple Clinical Practices. Cancer Cytopathol. 2015;123(5):282-8. doi:10.1002/cncy.21544. 6. Zhao, et al. Clinical Performance of the Food and Drug Administration-Approved High-Risk HPV Test for the Detection of High-Grade Cervicovaginal Lesions [published online ahead of print January 15, 2016]. Cancer Cytopathol. doi:10.1002/cncy.21687. 7. ACOG. Cervical Cancer Screening and Prevention. Obstet Gynecol. 2016;127:e1-20. doi:10.1097/AOG.0000000000001256. MISC-03952-001 Rev. 001 © 2016 Hologic, Inc. All rights reserved. Hologic, The Science of Sure, Pap+HPV Together, ThinPrep and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. This information is intended for medical professionals in the U.S. and other markets and is not intended as a product solicitation or promotion where such activities are prohibited. Because Hologic materials are distributed through websites, eBroadcasts and tradeshows, it is not always possible to control where such materials appear. For specific information on what products are available for sale in a particular country, please contact your local Hologic representative or write to diagnostic.solutions.com. Dear Valued Healthcare Partner: This month, we proudly celebrate the 20th Anniversary of the ThinPrep® Pap test. When the ThinPrep Pap test was introduced in 1996, all Pap testing was done via conventional “Pap smears,” and HPV testing was not a part of the cervical cancer screening algorithm. Since then, there has been a significant reduction in invasive cervical cancer in the U.S. 1 That’s something to celebrate. Today, more than 650 million ThinPrep Pap tests have been performed, with more than 6,000 ThinPrep processors installed globally. 2 The ThinPrep family is a leader in cervical cancer screening, with several notable “firsts”: • 3 * • The first FDA approval of glandular disease labeling. 3 • The first FDA approval for an automated imager, the ThinPrep® Imaging System. • The first and only FDA-approved collection media for use with FDA-approved HPV tests†. The ThinPrep family has been a leader in cervical cancer screening, and it has remained the trusted choice in Pap testing for the large majority of top healthcare providers and laboratories across the U.S. 2,4 Today, Pap+HPV Together™ (co-testing) is supported as the best strategy for detecting high-grade cervicovaginal lesions in women ages 30-65, according to recent studies. 5,6 Guidelines also recommend the use of co-testing as the preferred screening choice for women ages 30-65. 7 Hologic continues to stand behind this testing modality as the best screening strategy for women. While we celebrate our past, we continue to look to the future. The ThinPrep Pap test is the most trusted and widely used Pap test on the market. With your partnership, we have contributed to a decline in cervical cancer rates. We’re looking forward to delivering you innovative tools and advancing cervical cancer screening together for the next 20 years and beyond. Cordially, Kayla Shea Regional Business Manager, Hologic Canada 647-258-3617 [email protected] Come learn more at Hologic Booth #29 CAP-ACP 2016 July 9-12, 2016 THE THINPREP SYSTEM intraepithelial (LSIL) and more severe lesions in a variety of patient populations. † Aptima HR HPV test, Aptima GT test, Cervista® HPV HR Test, the Cervista® HPV 16/18 Test, the Roche cobas® HPV Test and the Digene Hybrid Capture System HPV DNA test.
Transcript of Hologic ThinPrep 20 years - CAP-ACPcap-acp.com/2016/images/Hologic_ThinPrep_20_years... · Regional...
Visit ThinPrep.com to learn more.
References: 1. National Cancer Institute. SEER Stat Fact Sheets: Cervix Uteri Cancer. http://seer.cancer.gov/statfacts/html/cervix.html. Accessed April 28, 2016. 2. Hologic, Inc. Data on File. 3. ThinPrep 2000 System [package insert]. MAN-02060-002 Rev. 001. Marlborough, MA: Hologic, Inc.; 2011. 4. U.S. News & World Report. Best Hospitals for Adult Gynecology. http://health.usnews.com/best-hospitals/rankings/gynecology. Published 2016. Accessed April 28, 2016. 5. Blatt, et al. Comparison of Cervical Cancer Screening Results Among 256,648 Women in Multiple Clinical Practices. Cancer Cytopathol. 2015;123(5):282-8. doi:10.1002/cncy.21544. 6. Zhao, et al. Clinical Performance of the Food and Drug Administration-Approved High-Risk HPV Test for the Detection of High-Grade Cervicovaginal Lesions [published online ahead of print January 15, 2016]. Cancer Cytopathol. doi:10.1002/cncy.21687. 7. ACOG. Cervical Cancer Screening and Prevention. Obstet Gynecol. 2016;127:e1-20. doi:10.1097/AOG.0000000000001256.
MISC-03952-001 Rev. 001 © 2016 Hologic, Inc. All rights reserved. Hologic, The Science of Sure, Pap+HPV Together, ThinPrep and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. This information is intended for medical professionals in the U.S. and other markets and is not intended as a product solicitation or promotion where such activities are prohibited. Because Hologic materials are distributed through websites, eBroadcasts and tradeshows, it is not always possible to control where such materials appear. For specific information on what products are available for sale in a particular country, please contact your local Hologic representative or write to diagnostic.solutions.com.
Dear Valued Healthcare Partner:
This month, we proudly celebrate the 20th Anniversary of the ThinPrep® Pap test. When the ThinPrep Pap test was introduced in 1996, all Pap testing was done via conventional “Pap smears,” and HPV testing was not a part of the cervical cancer screening algorithm. Since then, there has been a significant reduction in invasive cervical cancer in the U.S.1 That’s something to celebrate.
Today, more than 650 million ThinPrep Pap tests have been performed, with more than 6,000 ThinPrep processors installed globally.2 The ThinPrep family is a leader in cervical cancer screening, with several notable “firsts”:
• 3*• The first FDA approval of glandular disease labeling.3
• The first FDA approval for an automated imager, the ThinPrep® Imaging System.• The first and only FDA-approved collection media for use with FDA-approved HPV tests†.
The ThinPrep family has been a leader in cervical cancer screening, and it has remained the trusted choice in Pap testing for the large majority of top healthcare providers and laboratories across the U.S.2,4
Today, Pap+HPV Together™ (co-testing) is supported as the best strategy for detecting high-grade cervicovaginal lesions in women ages 30-65, according to recent studies.5,6 Guidelines also recommend the use of co-testing as the preferred screening choice for women ages 30-65.7 Hologic continues to stand behind this testing modality as the best screening strategy for women.
While we celebrate our past, we continue to look to the future. The ThinPrep Pap test is the most trusted and widely used Pap test on the market. With your partnership, we have contributed to a decline in cervical cancer rates. We’re looking forward to delivering you innovative tools and advancing cervical cancer screening together for the next 20 years and beyond.
Cordially,
Kayla SheaRegional Business Manager, Hologic Canada [email protected]
Come learn more at Hologic Booth #29CAP-ACP 2016 July 9-12, 2016
T H E T H I N P R E P S Y S T E M
intraepithelial (LSIL) and more severe lesions in a variety of patient populations.
† Aptima HR HPV test, Aptima GT test, Cervista® HPV HR Test, the Cervista® HPV 16/18 Test, the Roche cobas® HPV Test and the Digene Hybrid Capture System HPV DNA test.
